ImmunityBio’s (IBRX) meteoric rise this year has forced short sellers betting against the cancer drug developer to record roughly $492M in paper losses in the first 12 trading days of 2026, Bloomberg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results